Luminopia announced new clinical findings demonstrating the effectiveness and durability of its FDA-cleared therapy for amblyopia. The results were presented at the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 51st Annual Meeting. The three studies, conducted in collaboration with leading pediatric ophthalmology centers—including Ann & Robert H. Lurie Children’s Hospital of Chicago, UCSF Benioff Children’s Hospital, and the Wilmer Eye Institute at Johns Hopkins—analyzed real-world data from the PUPiL registry. This registry tracks outcomes in children treated with Luminopia’s digital therapeutic. The findings suggest that Luminopia’s treatment not only improves vision across a broad range of patients but also delivers sustained benefits after therapy ends, potentially addressing longstanding challenges in amblyopia care. According to the data, children treated with Luminopia showed consistent improvements in visual acuity across both younger and older age groups. Notably, patients aged 7 to 12—an age range where traditional therapies often yield limited success—experienced gains that exceeded those typically reported with standard clinical care. One of the most significant findings was the durability of treatment effects. While conventional patching therapies are associated with regression rates of 20% to 25% after discontinuation, children who completed Luminopia treatment showed regression rates of approximately 3%. These stable outcomes were observed across diverse patient groups, regardless of age, severity, type of amblyopia, or prior treatments. The studies also highlighted meaningful improvements in children with severe amblyopia, a group that historically has been difficult to treat. Among patients with visual acuity of 20/100 or worse, 46% achieved improvements of two or more lines on an eye chart. Even greater gains—averaging 2.8 lines—were seen in patients with visual acuity of 20/200 or worse. “These findings demonstrate the potential of Luminopia to address some of the most challenging cases of amblyopia,” said Scott Xiao, founder and CEO of Luminopia. “The real-world data show that children—even those with severe or treatment-resistant amblyopia—can achieve meaningful vision gains.”